1. Lifetime risk for development of atrial fibrillation the Framingham Heart Study;Lloyd‐Jones;Circulation,2004
2. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation;Yao;J Am Heart Assoc,2016
3. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge;Lippi;Int J Stroke,2020
4. Global, Regional, and National Prevalence, Incidence, Mortality, and Risk Factors for Atrial Fibrillation, 1990–2017: Results from the Global Burden of Disease Study 2017;Dai,2020
5. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study;Chugh;Circulation,2014